Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (101-110 of 189) with videos related to

Pageof 19
Sort By:
The Journal of Biological Chemistry|November 9, 2016
Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and SrcMei Sun, Lin Yang, Richard I Feldman, et al.
Archiv Der Pharmazie|October 1, 1984
Syntheses and anti-inflammatory activities of substituted arylamino-(N'-benzylidene)acetohydrazides and derivativesM Verma, V R Gujrati, M Sharma, et al.
Leukemia|October 6, 2001
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapyM V Blagosklonny, T Fojo, K N Bhalla, et al.
Leukemia|April 5, 2014
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cellsW Fiskus, S Sharma, B Shah, et al.
Leukemia|March 22, 2017
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cellsW Fiskus, S Sharma, B Shah, et al.
Leukemia|July 8, 2015
HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonistS G T Devaraj, W Fiskus, B Shah, et al.
International Journal of Radiation Oncology, Biology, Physics|February 25, 1999
'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosisS H Burri, C N Kim, G Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumorsK N Bhalla, G N Kumar, U K Walle, et al.
Breast Cancer Research and Treatment|July 25, 2012
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cellsWarren Fiskus, Stacey L Hembruff, Rekha Rao, et al.
Leukemia|December 9, 2014
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cellsW Fiskus, S Sharma, S Saha, et al.
Pageof 19

Showing results (101-110 of 189) with videos related to

Sort By:
Pageof 19
The Journal of Biological Chemistry|November 9, 2016
Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and SrcMei Sun, Lin Yang, Richard I Feldman, et al.
Archiv Der Pharmazie|October 1, 1984
Syntheses and anti-inflammatory activities of substituted arylamino-(N'-benzylidene)acetohydrazides and derivativesM Verma, V R Gujrati, M Sharma, et al.
Leukemia|October 6, 2001
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapyM V Blagosklonny, T Fojo, K N Bhalla, et al.
Leukemia|April 5, 2014
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cellsW Fiskus, S Sharma, B Shah, et al.
Leukemia|March 22, 2017
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cellsW Fiskus, S Sharma, B Shah, et al.
Leukemia|July 8, 2015
HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonistS G T Devaraj, W Fiskus, B Shah, et al.
International Journal of Radiation Oncology, Biology, Physics|February 25, 1999
'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosisS H Burri, C N Kim, G Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumorsK N Bhalla, G N Kumar, U K Walle, et al.
Breast Cancer Research and Treatment|July 25, 2012
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cellsWarren Fiskus, Stacey L Hembruff, Rekha Rao, et al.
Leukemia|December 9, 2014
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cellsW Fiskus, S Sharma, S Saha, et al.
Pageof 19